Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir PK Interaction with Antiretrovirals in Healthy Volunteers
NCT04385719Phase 2Completed
- Sponsor
- Makerere University
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of remdesivir in Ebola virus disease (EVD) (3 arms), sponsored by Makerere University. Primary endpoints: Number of adverse events categorised by body system at 30 days, Peak Concentration of remdesivir in PBMCs and Plasma at 24 hours and 3 more. Started May 2021; status: completed.
02
Drugs
remdesivir
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04385719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385719.